XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The com...
2026-04-30T14:05:11.000Z - 12 days ago
AKAN RDAC
2026-04-29T13:28:07.000Z - 13 days ago
Wed, 29 Apr 2026 08:58:00 -0400 - 13 days ago
2026-03-24T23:50:33.000Z - 7 weeks ago
2026-03-20T21:50:34.000Z - 7 weeks ago
2026-03-20T20:20:19.000Z - 7 weeks ago
Fri, 20 Mar 2026 16:10:00 -0400 - 7 weeks ago
2026-03-10T11:35:43.000Z - 2 months ago
XAIR
2026-02-27T22:56:21.000Z - 2 months ago
2026-02-27T21:35:58.000Z - 2 months ago
Fri, 27 Feb 2026 16:30:00 -0500 - 2 months ago
2026-01-29T22:31:47.000Z - 3 months ago
2026-01-29T21:40:19.000Z - 3 months ago
Thu, 29 Jan 2026 16:05:00 -0500 - 3 months ago
Fri, 23 Jan 2026 16:10:00 -0500 - 3 months ago
Tue, 13 Jan 2026 09:28:00 -0500 - 4 months ago
2026-01-13T13:11:13.000Z - 4 months ago
2026-01-13T12:53:54.000Z - 4 months ago
2026-01-13T12:35:15.000Z - 4 months ago
Wed, 24 Dec 2025 16:00:00 -0500 - 4 months ago
2025-04-07T13:20:15.000Z - 1 year ago
Mon, 07 Apr 2025 09:15:00 -0400 - 1 year ago
2024-08-14T13:19:59.000Z - 1 year ago
Wed, 14 Aug 2024 09:15:00 -0400 - 1 year ago
2024-06-05T13:20:43.000Z - 2 years ago
Wed, 05 Jun 2024 09:15:00 -0400 - 2 years ago
2024-03-22T15:33:36.000Z - 2 years ago
ATOS BNTX CERS CMRX CRNX HOTH
2024-03-20T14:18:13.000Z - 2 years ago
Wed, 20 Mar 2024 10:15:00 -0400 - 2 years ago
2023-10-20T20:02:09.000Z - 2 years ago
2023-10-20T20:00:59.000Z - 2 years ago
Fri, 20 Oct 2023 16:00:00 -0400 - 2 years ago
Mon, 20 Sep 2021 09:05:00 -0400 - 5 years ago